Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD)

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 543-565

  Oades, Robert D ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

ADHD; attention; dopamine; genetics; glia; impulsivity; prefrontal cortex; serotonin; venlafaxine

Indexed keywords

CITALOPRAM; DOPAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT; RACLOPRIDE C 11; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN TRANSPORTER; VANOXERINE; VENLAFAXINE;

ATTENTION; ATTENTION DEFICIT DISORDER; BINDING SITE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENETICS; HUMAN; IMPULSIVENESS; MONOTHERAPY; NEUROIMAGING; NEUROPSYCHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL STATUS; TANDEM REPEAT; TASK PERFORMANCE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS;

EID: 50349088610     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00926-6     Document Type: Review

References (156)

1. Abikoff H.B., Hechtman L., Klein R.G., Gallagher R., Fleiss K., Etcovitch J., Cousins L., Greenfield B., Maertin D., and Pollack S. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J. Am. Acad. Child. Adolesc. Psychiatry 43 (2004) 820-829
2. Asherson P. Attention deficit hyperactivity disorder in the post-genomic era. Eur. Child. Adolesc. Psychiatry 13 (2004) 50-66
3. Asherson P., Brookes K.-J., Franke B., Chen W., Gill M., Ebstein R.P., Buitelaar J., Banaschewski T., Sonuga-Barke E.J.S., Eisenberg J., Manor I., Miranda A., Oades R.D., Roeyers H., Rothenberger A., Sergeant J.A., Steinhausen H.-C., and Faraone S.V. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined type ADHD. Am. J. Psychiatry 164 (2007) 674-677
4. Baker G.B., Bornstein R.A., Rouget A.C., Ashton S.E., Van Muyden J.C., and Coutts R.T. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol. Psychiatry 29 (1991) 15-22
5. Banerjee E., Sinha S., Chatterjee A., Gangopdhyay P.K., Singh M., and Nandogopal K. A family-based study of Indian subjects from Kolkata reveals allelic association of the serotonin transporter intron-2 (STin2) polymorphism and attention-deficit-hyperactivity disorder (ADHD). Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 (2006) 361-366
6. Banks M.L., Czoty P.W., Gage H.D., Bounds M.C., Garg P.K., Garg S., and Nader M.A. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 33 (2008) 219-225
7. 1B receptors in nucleus accumbens efferents enhance both rewarding and aversive effects of cocaine. Eur. J. Neurosci. 25 (2007) 3125-3131
8. Beitchman J.H., Baldasarra L., Mik H., De Luca V., King N., Bender D., Ehtesham S., and Kennedy J.L. Serotonin transporter polymorphisms and persistent, pervasive childhood aggression. Am. J. Psychiatry 163 (2006) 1103-1105
9. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 (2005) 237-248
10. Biederman J., Faraone S.V., Monuteaux M., Bober M., and Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol. Psychiatry 55 (2004) 692-700
11. Biederman J., Mick E.O., Surman C., Doyle R., Hammerness P., Michel E., Martin J., and Spencer T.J. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7 (2007) 49
12. Biederman J., Petty C.R., Wilens T.E., Fraire M.G., Purcell C.A., Mick E., Monuteaux M.C., and Faraone S.V. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am. J. Psychiatry 165 (2007) 107-115
13. 1 agonist SKF 82958. Neuropharmacology 49 (2005) 350-358
14. Brookes K.-J., Xu X., Chen W., Zhou K., Neale B.M., Lowe N., Aneley R., Franke B., Gill M., Ebstein R.P., Buitelaar J., Sham P., Cambell D., Knight J., Andreou P., Altink M., Arnold R., Boer F., Buschgens C., Butler L., Christiansen H., Feldman L., Fleischman K., Fliers E., Howe-Forbes R., Goldfarb A., Heise A., Gabriels I., Lubetzki I., Marco R., Medad S., Minderaa R.B., Mulas F., Müller U.C., Mulligan A., Rabin K., Rommelse N.N.J., Sethna V., Sorohan J., Uebel H., Psychogiou L., Weeks A., Barrett R., Craig I., Banaschewski T., Sonuga-Barke E.J.S., Eisenberg J., Kuntsi J., Manor I., McGuffin P., Miranda A., Oades R.D., Plomin R., Roeyers H., Rothenberger A., Sergeant J.A., Steinhausen H.-C., Taylor E.A., Thompson M.J., Faraone S.V., Asherson P., and Johansson L. Analysis of 51 candidate genes in DSM-IV combined subtype attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry 11 (2006) 934-953
15. Budygin E.A., Brodie M.S., Sotnikova T.D., Mateo Y., John C.E., Cyr M., Gainetdinov R.R., and Jones S.R. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7781-7786
16. Buitelaar J.K., Barton J., Danckaerts M., Friedrichs E., Gillberg C., Hazell P.L., Hellemans H., Johnson M., Kalverdijk L.J., Masi G., Michelson D., Revol O., San Sebastian J., Zhang S., and Zuddas A. A comparison of North American versus non-North American ADHD study populations. Eur. Child. Adolesc. Psychiatry 15 (2006) 177-181
17. Burgio-Murphy A., Klorman R., Shaywitz S.E., Fletcher J.M., Marchione K.E., Holahan J., Stuebing K.K., Thatcher J.E., and Shaywitz B.A. Error-related event-related potentials in children with attention-deficit hyperactivity disorder, oppositional defiant disorder, reading disorder, and math disorder. Biol. Psychol. 75 (2007) 75-86
18. Cadoret R.J., Langbehn D., Caspers K., Troughton E.P., Yucuis R., Sandhu H.K., and Philibert R. Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. Compr. Psychiatry 44 (2003) 88-101
19. Castellanos F.X., Elia J., Kruesi M.J.P., Gulotta C.S., Mefford I.N., Potter W.Z., Ritchie G.F., and Rapoport J.L. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 52 (1994) 305-316
20. Castellanos F.X., Elia J., Kruesi M.J.P., Marsh W.L., Gulotta C.S., Potter W.Z., Ritchie G.F., Hamburger S.D., and Rapoport J.L. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14 (1996) 125-137
21. 3H] 5HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 32 (1993) 737-743
22. Committee on children and disabilities and committee on drugs. Medication for children with attentional disorders. Pediatrics 98 (1996) 301-304
23. Consolo S., Ramponi S., Ladinsky H., and Baldi G. A critical role for D1 receptors in the 5-HT1a mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Brain Res. 707 (1996) 320-325
24. Curran S., Purcell S., Craig I., Asherson P., and Sham P. The serotonin transporter gene as a QTL for ADHD. Am. J. Med. Genet. 134B (2005) 42-47
25. De Bruijn E.R.A., Hulstijn W., Verkes R.J., Ruigt G.S.F., and Sabbe B.G.C. Drug-induced stimulation and suppression of action monitoring in healthy volunteers. Psychopharmacology 177 (2004) 151-160
26. Dewey S.L., Smith G.S., Logan J., Ding Y.-S., King P., Pappas N.S., Brodie J.D., and Ashby C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15 (1995) 821-829
27. Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cereb. Cortex 17 (2007) i161-i170
28. Di Giovanni G., Pierucci M., Di Matteo V., and Esposito E. Serotonin/dopamine interactions: electrophysiological evidence. In: Di Giovanni G., Di Matteo V., and Esposito E. (Eds). Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance (2008), Elsevier, Amsterdam 45-71
29. Di Mascio M., Di Giovanni G., Di Matteo V., Prisco S., and Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain. Res. Bull. 46 (1998) 547-554
30. Di Matte V., De Blasi A., Di Giulio C., and Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci. 22 (2001) 229-232
31. Doherty M.D., and Pickel V.M. Targeting of serotonin 1a receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain. J. Comp. Neurol. 433 (2001) 390-400
32. Domschke K., Sheehan K., Lowe N., Kirley A., Mullins C., O'Sullivan R., Freitag C., Becker T., Conroy J., Fitzgerald M., Gill M., and Hawi Z. Association analysis of the monoamine oxidase A and B genes with attention deficit hyperactivity disorder (ADHD) in an Irish sample: preferential transmission of the MAO-A 941G allele to affected children. Am. J. Med. Genet. 134B (2005) 110-114
33. Donnelly M., Zametkin A.J., Rapoport J.L., Ismond D.R., Weingartner H., Lane E., Oliver J., Linnoila M., and Potter W.Z. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin. Pharmacol. Ther. 39 (1986) 72-81
34. Eisenberg J., Mei-Tal G., Steinberg A., Tartakovsky E., Zohar A., Gritsenko I., Nemanov L., and Ebstein R.P. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am. J. Med. Genet. 88 (2003) 497-502
35. Elfving B., Madsen J., and Knudsen G.M. Neuroimaging of the serotonin reuptake site requires high-affinity ligands. Synapse 61 (2007) 882-888
36. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., and Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18] fluorodopa positron emission tomography study. J. Neurosci. 18 (1998) 5901-5907
37. Ernst M., Zametkin A.J., Matochik J.A., Pascualvaca D., Jons P.H., and Cohen R.M. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am. J. Psychiatry 156 (1999) 1209-1215
38. Fallgatter A.J., Herrmann M.J., Roemmler J., Ehlis A.-C., Wagener A., Heidrich A., Ortega G., Zeng Y., and Lesch K.-P. Allelic variation of serotonin transporter function modulates the brain electrical response for error processing. Neuropsychopharmacology 29 (2005) 1506-1511
39. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., and Sklar P. Molecular genetics of attention deficit hyperactivity disorder. Biol. Psychiatry 57 (2005) 1313-1323
40. Faraone S.V., Sergeant J.A., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
41. Ferrari P.F., Van Erp A.M., Tornatzky W., and Miczek K.A. Accumbal dopamine and serotonin in anticipation of the next aggressive episode in rats. Eur. J. Neurosci. 17 (2003) 371-378
42. Findling R.L., Greenhill L.L., McNamara N.K., Demeter C.A., Kotler L.A., O'Riordan M.A., Myers C., and Reed M.D. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 17 (2007) 433-445
43. Findling R.L., Schwartz M.A., Flannery D.J., and Manos M.J. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J. Clin. Psychiatry 58 (1996) 178-179
44. Floden D., Alexander M.P., Kubu C.S., and Stuss D.T. Impulsivity and risk-taking behavior in focal frontal lobe lesions. Neuropsychologia 46 (2008) 213-223
45. Flory J.D., Newcorn J.H., Miller C., Harty S., and Halperin J.M. Serotonergic function in children with attention-deficit hyperactivity disorder relationship to later antisocial personality disorder. Br. J. Psychiatry 190 (2007) 410-414
46. Gainetdinov R.R., and Caron M.G. Monoamine transporters: from genes to behavior. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 261-284
47. Garcia-Cabezas M.A., Rico B., Sanchez-Gonzalez M.A., and Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage 34 (2007) 965-984
48. Gastfriend D.R., Biederman J., and Jellinek M.S. Desipramine in the treatment of attention deficit disorder in adolescents. Psychopharmacol. Bull. 21 (1985) 144-145
49. Gogos J.A., Morgan M., Luine V.N., Santha M., Ogawa S., Pfaff D.W., and Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9991-9996
50. Goto Y., Otani S., and Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53 (2007) 583-587
51. Gould G.C., Altamirano A.V., Javors M.A., and Frazer A. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol. Psychiatry 59 (2006) 408-414
52. Gualtieri C.T., and Johnson L.G. Medications do not necessarily normalize cognition in ADHD patients. J. Atten. Disord. 11 (2008) 459-469
53. Guimaraes A.P.M., Zeni C., Polanczyk G.V., Genro J.P., Roman T., Rohde L.A., and Hutz M.H. Serotonin genes and attention deficit/hyperactivity disorder in a Brazilian sample: preferential transmission of the HTR2A 452His allele to affected boys. Am. J. Med. Genet. Part B 144B (2007) 69-73
54. Haddjeri N., Fare C., Lucas G., Mnie-Filali O., Astier B., Renaud B., Blier P., and Debonnel G. In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system. Int. J. Neuropsychopharmacol. 7 (2004) 391-399
55. 1B receptor gene in 273 nuclear families from a multi-centre sample. Mol. Psychiatry 7 (2002) 718-725
56. Hawi Z., Foley D., Kirley A., McCarron M., Fitzgerald M., and Gill M. Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD): no evidence for association in the Irish population. Mol. Psychiatry 6 (2001) 420-424
57. Hedges D., Reimherr F.W., Rogers A., Strong R., and Wender P.H. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol. Bull. 31 (1995) 779-783
58. Hesse S., Ballaschkle O., Barthel H., von Cramon D.Y., and Sabri O. The striatal dopamine transporter availability is reduced in adults with attention-deficit/hyperactivity disorder. J. Nucl. Med. 47 (2006) 142P
59. Higley J.D., King S.T., Hasert M.F., Champoux M., Suomi S.J., and Linnoila M. Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behavior in Rhesus Macaque females. Neuropsychopharmacology 14 (1996) 67-76
60. Hirst W.D., Cheung N.Y., Rattray M., Price G.W., and Wilkin G.P. Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenylyl cyclase. Mol. Brain. Res. 61 (1998) 90-99
61. Iversen S.D., and Iversen L.L. Dopamine: 50 years in perspective. Trends Neurosci. 30 (2007) 188-193
62. Jacobs B.L., and Fornal C.A. Serotonin and behavior: a general hypothesis. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 461-469
63. Jensen P.S., and Arnold L.E. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113 (2004) 754-761
64. Kennedy S.H., Konarski J.Z., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., and Mayberg H.S. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am. J. Psychiatry 164 (2007) 778-788
65. Kent L., Doerry U., Hardy E., Parmar R., Gingell K., Hawi Z., Kirley A., Lowe N., Fitzgerald M., Gill M., and Craddock N. Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): analysis and pooled analysis. Mol. Psychiatry 7 (2002) 908-912
66. Kruesi M.J.P., Rapoport J.L., Hamburger S.D., Hibbs E., Potter W.Z., Lenane M., and Brown G.L. Cerebrospinal fluid monoamine metabolites, aggression and impulsivity in disruptive behavior disorders of children and adolescents. Arch. Gen. Psychiatry 47 (1990) 419-426
67. Krusch D.A., Klorman R., Brumaghim J.T., Fitzpatrick P.A., Borgstedt A.D., and Strauss J.S. Methylphenidate slows reactions of children with attention deficit disorder during and after an error. J. Abnorm. Child Psychol. 24 (1996) 633-650
68. Leonard B.E., McCartan D., White J., and King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum. Psychopharmacol. Clin. Exp. 19 (2004) 151-180
69. Levesque M., and Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11888-11893
70. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust. N.Z. J. Psychiatry 25 (1991) 277-283
71. Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 29 (2004) 1589-1596
72. Levy F., and Hobbes G. Does haloperidol block methylphenidate? Motivation or attention?. Psychopharmacology 126 (1996) 70-79
73. Li J., Wang Y., Zhou R., Zhang H., Yang H., Yang L., Wang B., and Faraone S.V. Association between polymorphisms in serotonin transporter gene and attention deficit hyperactivity disorder in Chinese Han subjects. Am. J. Med. Genet. Part B 144B (2007) 14-19
74. Loo S.K., Specter E., Smolen A., Hopfer C., Teale P.D., and Reite M.L. Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 42 (2003) 986-993
75. Luthman J., Frederiksson A., Sundström E., Jonsson G., and Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain Res. 33 (1989) 267-277
76. Maidment I.D. The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J. Psychopharmacol. 17 (2003) 332-336
77. Manor I., Corbex M., Eisenberg J., Gritsenkso I., Bachner-Melman R., Tyano S., and Ebstein R.P. Association of the dopamine D5 receptor with attention deficit hyperactivity disorder (ADHD) and scores on a continuous performance test (TOVA). Am J. Med. Genet. 127B (2004) 73-77
78. Manor, I., Laibe, E., Eisenberg, J., Meidad, S., Lerer, E., Israel, S., Gritsenko, I., Tyano, S., Faraone, S.V. and Ebstein, R.P. (2008) Association between tryptophan hydroxylase 2 performance on a continuance performance test (T.O.V.A.) and response to methylphenidate in ADHD participants. Am. J. Med. Genet Part B, DOI: 10.1002/ajmg.b.30702.
79. Manor I., Tyano S., Eisenberg J., Bachner-Melman R., Kotler M., and Ebstein R.P. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Mol. Psychiatry 7 (2002) 790-794
80. Manuck S.B., Bleil M.E., Petersen K.L., Flory J.D., Mann J.J., Ferrell R.E., and Muldoon M.F. The socio-economic status of communities predicts variation in brain serotonergic responsivity. Psychol. Med. 35 (2005) 519-528
81. Mateo Y., Budygin E.A., John C.E., and Jones S.R. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 372-377
82. Mendlin A., Martin F.J., and Jacobs B.L. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience 93 (1999) 897-906
83. Martin-Ruiz R., Ugedo L., Honrubia M.A., Mengod G., and Artigas F. Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J. Neurochem. 77 3 (2001) 762-775
84. Meneses A. The 5-HT system and cognition. Neurosci Biobehav. Rev 23 (1999) 1111-1125
85. Meyer A., and Sagvolden T. Fine motor skills in South African children with symptoms of ADHD: influence of subtype, gender, age, and hand dominance. Behav. Brain Funct. 2 (2006) 33
86. Michelsen, K.A., Prickaerts, J. and Steinbusch, H.W.M. (2008) The dorsal raphe nucleus and serotonin - implications for neuroplasticity linked to major depression and Alzheimer's disease. In: Di Giovanni, G., Di Matteo, V., and Esposito, E. (Eds.), Serotonin-Ddopamine Interaction: Experimental Evidence and Therapeutic Relevance.
87. Michelsen K.A., Schmitz C., and Steinbusch H.W.M. The dorsal raphe nucleus-from silver stainings to a role in depression. Brain Res. Rev. 55 (2007) 329-342
88. Millan M.J., Lejeune F., and Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14 (2007) 114-138
89. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., and Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res. 1029 (2004) 120-123
90. Morrison J.H., and Foote S.L. Noradrenergic and serotonergic innervation of the cortical, thalamic, and tectal visual structures in old and new world monkeys. J. Comp. Neurol. 243 (1986) 117-138
91. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H.W.M., and Leonard B.E. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect Disord. 98 (2007) 143-151
92. 2A/2C receptors. Synapse 62 (2007) 14-21
93. Navailles S., Moison D., Cunningham K.A., and Spampinato U. Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology 33 (2008) 237-246
94. Neale B.M., Sham P.C., Purcell S., Banaschewski T., Buitelaar J., Franke B., Sonuga-Barke E.J.S., Ebstein R.P., Eisenberg J., Mulligan A., Gill M., Manor I., Miranda A., Mulas F., Oades R.D., Roeyers H., Rothenberger A., Sergeant J.A., Steinhausen H.-C., Taylor E.A., Thompson M., Zhou K., Asherson P., and Faraone S.V. Population differences in the international multi-centre ADHD gene project. Genet. Epidemiol. 32 (2007) 98-107
95. Nomura M., Kusumi I., Kaneko M., Masui T., Daiguji M., Ueno T., Koyama T., and Nomura Y. Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology 187 (2006) 30-35
96. Nyman E.S., Ogdie M.N., Loukola A., Varilo T., Taanila A., Hurtig T., Moilanen I.K., Loo S.K., McGough J.J., Järvelin M.-R., Smalley S.L., Nelson S.F., and Peltonen L. ADHD candidate gene study in a population-based birth cohort: association with DBH and DRD2. J. Am. Acad. Child. Psychiatry 46 (2007) 1614-1621
97. Oades R.D. The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. Neurosci. Biobehav. Rev. 9 (1985) 261-283
98. Oades R.D. Attention deficit disorder with hyperactivity (ADDH): the contribution of catecholaminergic activity. Prog. Neurobiol. 29 (1987) 365-391
99. Oades R.D. Dopamine may be 'hyper' with respect to noradrenaline metabolism, but 'hypo' with respect to serotonin metabolism in children with ADHD. Behav. Brain. Res. 130 (2002) 97-101
100. Oades R.D. The roles of norepinephrine and serotonin in ADHD. In: Gozal D., and Molfese D.L. (Eds). Attention Deficit Hyperactivity Disorder: From Genes to Animal Models to Patients (2005), Humana Press, Totowa, NY 97-130
101. Oades R.D. Function and dysfunction of monoamine interactions in children and adolescents with AD/HD. In: Levin E.D. (Ed). Neurotransmitter Interactions and Cognitive Function (2006), Birkhäuser Verlag, Basel 207-244
102. Oades R.D. The role of the serotonin system in ADHD: treatment implications. Expert Rev. Neurother. 7 (2007) 1357-1374
103. Oades R.D., and Halliday G.M. The ventral tegmental (A 10) system. Neurobiology I: anatomy and connectivity. Brain Res. Rev. 12 (1987) 117-165
104. Oades R.D., and Müller B.W. The development of conditioned blocking and monoamine metabolism in children with attention-deficit-hyperactivity disorder or complex tics and healthy controls: an exploratory analysis. Behav. Brain Res. 88 (1997) 95-102
105. Oades R.D., Slusarek M., Velling S., and Bondy B. Serotonin platelet-transporter measures in childhood attention-deficit/hyperactivity disorder (ADHD): clinical versus experimental measures of impulsivity. World J. Biol. Psychiatry 3 (2002) 96-100
106. O'Neill M.F., Heron-Maxwell C.L., and Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine and MK-801 but not D-1 agonist c-APB. Pharmacol. Biochem. Behav. 63 (1999) 237-244
107. Overtoom C.C.E., Verbaten M.N., Kemner C., Kenemans J.L., van Engeland H., Buitelaar J.K., van der Molen M.W., Van der Gugten J., Westenburg H.G.M., Maes R.A.A., and Koelega H.S. Effects of methylphenidate, desipramine and L-DOPA on attention and inhibition in children with attention deficit hyperactivity disorder. Behav. Brain Res. 145 (2003) 7-15
108. Park S.B., Coull J.T., McShane R.H., Young A.H., Sahakian B.J., Robbins T.W., and Cowen P.J. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 33 (1994) 575-588
109. Pelham W.E., and Murphy D.A. Attention deficit disorder. In: Pelham W.E., and Murphy D.A. (Eds). International Perspectives in Behavioral Medicine (1990), International Perspectives in Behavioral Medicine, Norwood, NJ 1-30
110. Phelix C.F., and Broderick P.A. Light microscopic immunocytochemical evidence for converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res. Bull. 37 (1995) 37-41
111. Popper C.W. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. 9 (2000) 605-646
112. Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdere P., Caccia S., Esposito E., and Spampinato U. 5-HT(2A) and 5-HT(2C/2B) receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 (2002) 311-324
113. Preuss U.W., Koller G., Bondy B., Bahlmann M., and Soyka M. Impulsive traits and 5-HT2A receptor promoter polymorphism in alcohol dependents: possible association but no influence of personality disorders. Neuropsychobiology 43 (2001) 186-191
114. Qian Q., Wang Y., Zhou R., Li J., Wang B., Glatt S.J., and Faraone S.V. Family-based and case-control association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am. J. Med. Genet. Part B 118 (2003) 103-109
115. Reuter M., Kirsch P., and Hennig J. Inferring candidate genes for attention deficit hyperactivity disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). J. Neural Transm. 113 (2006) 929-938
116. Reuter M., Kuepper Y., and Hennig J. Association between a polymorphism in the promoter region of the TPH2 gene and the personality trait of harm avoidance. Int. J. Neuropsychopharmacol. 10 (2007) 401-404
117. Ribases, M., Ramos-Quiroga, J.A., Hervas, A., Bosch, R., Bielsa, A., Gastaminza, X., Artigas, J., Rodriguez-Ben, S., Estivill, X., Casas, M., Cormand, B. and Bayes, M. (2007) Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol. Psychiatry, doi:10.1038/sj.mp.4002100.
118. Riikonen R.S., Nokelainen P., Valkonen K., Kolemainen A.I., Kupulainen K.I., Koenoenen M., Vanninen R.-L.S., and Kuikka J.T. Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-β-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry. Biol. Psychiatry 57 (2005) 1565-1572
119. Roesch M.R., Calu D.J., and Schoenbaum G. Dopamine neurons encode the better option in rats deciding between differently delayed or sized rewards. Nat. Neurosci. 10 (2007) 1615-1624
120. Rommelse N.N.J., Altink M.E., Oosterlaan J., Buschgens C.J.M., Buitelaar J., de Sonneville L.M.J., and Sergeant J.A. Motor control in children with ADHD and non-affected siblings: deficits most pronounced using the left hand. J. Child. Psychol. Psychiatry 48 (2007) 1071-1079
121. Rosa-Neto P., Lou H.C., Cumming P., Pryds O., Karrebaek H., Lunding J., and Gjedde A. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 25 (2005) 868-876
122. Rubia K., Lee F., Cleare A.J., Tunstall N., Fu C.H.Y., Brammer M.J., and McGuire P.K. Tryptophan depletion reduces right inferior prefrontal activation during no-go trials in fast, event-related fMRI. Psychopharmacology 179 (2004) 791-803
123. Rubia K., Smith A.B., and Taylor E.A. Performance of children with attention deficit hyperactivity disorder (ADHD) on a test battery of impulsiveness. Child Neuropsychol. 13 (2007) 276-304
124. Russell V.A., Oades R.D., Tannock R., Auerbach J., Killeen P.R., Johansen E.B., and Sagvolden T. Response variability in attention-deficit/hyperactivity disorder: a neuronal and glial energetics hypothesis. BMC Behav. Brain Funct. 2 (2006) 30
125. Sagvolden T., Johansen E.B., Aase H., and Russell V.A. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav. Brain Sci. 28 (2005) 397-468
126. Schachar R.J., Chen S., Logan G.D., Ornstein T.J., Crosbie J., Ickowicz A., and Pakulak A. Evidence for an error monitoring deficit in attention deficit hyperactivity disorder. J. Abnorm. Child. Psychol. 32 (2004) 285-293
127. Scheres A., Oosterlaan J., and Sergeant J.A. Response execution and inhibition in children with AD/HD and other disruptive disorders: the role of behavioural activation. J. Child Psychol. Psychiatry 42 (2001) 347-357
128. Schmidt L.A., Fox N.A., and Hamer D.H. Evidence for a gene-gene interaction in predicting children's behavior problems: association of serotonin transporter short and dopamine receptor D4 long genotypes with internalizing and externalizing behaviors in typically developing 7-year-olds. Dev. Psychopathol. 19 (2007) 1105-1116
129. Schulz K.P., McKay K.E., Newcorn J.H., Sharma V., Gabriel S., and Halperin J.M. Serotonin function and risk for alcoholism in boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 18 (1998) 10-17
130. Shaw P., Eckstrand K., Sharp W., Blumenthal J., Lerch J.P., Greenstein D., Clasen L., Evans A., Giedd J.N., and Rapoport J.L. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 19649-19654
131. Smoller J.W., Biederman J., Arbeitman L., Doyle A.E., Fagerness J., Perlis R.H., Sklar P., and Faraone S.V. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. Biol. Psychiatry 59 (2006) 460-467
132. Snoek H., van Goozen S.H.M., Matthys W., Sigling H.O., Koppeschaar H.P.F., Westenberg H.G.M., and van Engeland H. Serotonergic functioning in children with oppositional defiant disorder: a sumatriptan challenge study. Biol. Psychiatry 51 (2002) 319-325
133. Sonuga-Barke E.J.S. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol. Psychiatry 57 (2005) 1231-1238
134. Stadler C., Schmeck K., Nowraty I., Müller W.E., and Poustka F. Platelet 5-HT uptake in boys with conduct disorder. Neuropsychobiology 50 (2004) 244-251
135. Stoff D.M., Pollock L., Vitiello B., Behar D., and Bridger W.H. Reduction of (3H)-imipramine binding sites on platelets of conduct-disordered children. Neuropsychopharmacology 1 (1987) 55-62
136. Swanson J.M., Kinsbourne M., Nigg J.T., Lanphear B., Stefanotos G.A., Volkow N.D., Taylor E.A., Casey B.J., Castellanos F.X., and Wadhwa P.D. Etiologic subtypes of attention-deficit/hyperactivity disorder: Brain imaging, molecular genetic and encironmental factors and the dopamine hypothesis. Neuropsychol. Rev. 17 (2007) 39-59
137. Telang F.W., Volkow N.D., Levy A., Logan J., Wong C., and Wang G.J. Distribution of tracer levels of cocaine in the human brain as assessed with averaged [11C]cocaine images. Synapse 31 (1999) 290-296
138. Todd R.D., and Botteron K.N. Is attention-deficit/hyperactivity disorder an energy deficiency syndrome?. Biol. Psychiatry 50 (2001) 151-158
139. Tucha O., Mecklinger L., Laufkoetter R., Kaunzinger I., Paul G.M., Klein H.E., and Lange K.W. Clustering and switching on verbal and figural fluency functions in adults with attention deficit hyperactivity disorder. Cogn. Neuropsychiatry 10 (2005) 231-248
140. 1A receptors in the modulation of stress-induced lactate metabolism in the medial prefrontal cortex and basolateral amygdala. Psychopharmacology 186 (2006) 218-225
141. Uzbekov M.G. Hyperkinetic syndrome as a manifestation of a disturbance of metabolism and mental development. In: Oades R.D. (Ed). Attention-Deficit/Hyperactivity Disorder and the Hyperkinetic Syndrome: Current Ideas and Ways Forward (2006), Nova Science Publishers, Inc., Hauppauge, NY 133-154
142. van der Plasse G., and Feenstra M.G.P. Serial reversal learning and acute tryptophan depletion. Behav. Brain Res. 186 (2007) 23-31
143. van Goozen S.H.M., Fairchild G., Snoek H., and Harold G.T. The evidence for a neurobiological model of childhood antisocial behavior. Psychol. Bull. 133 (2007) 149-182
144. Van Meel C.S., Heslenfeld D.J., Oosterlaan J., and Sergeant J.A. Adaptive control deficits in attention-deficit/hyperactivity disorder (ADHD): the role of error processing. Psychiatry Res. 151 (2007) 211-220
145. Vertes R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol. 313 (1991) 643-668
146. Volkow N.D., Wang G.-J., Newcorn J.H., Fowler J.S., Telang F.W., Solanto M.V., Logan J., Wong C., Ma Y., Swanson J.M., Schulz K.P., and Pradhan K. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage 34 (2007) 1182-1190
147. Volkow N.D., Wang G.-J., Newcorn J.H., Telang F.W., Solanto M.V., Fowler J.S., Logan J., Ma Y., Schulz K., Pradhan K., Wong C., and Swanson J.M. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64 (2007) 932-940
148. Vollmar P., Haghikia A., Dermietzel R., and Faustmann P.M. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int. J. Neuropsychopharmacol. 11 (2007) 111-117
149. Walderhaug E., Lunde H., Nordvik J.E., Landro N.I., Refsum H., and Magnusson A. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. Psychopharmacology 164 (2002) 385-391
150. Weikop P., Kehr J., and Scheel-Kruger J. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. J. Psychopharmacol. 21 (2007) 795-804
151. Weikop P., Yoshitake T., and Kehr J. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur. Neuropsychopharmacol. 17 (2007) 658-671
152. Wiersema J.R., van der Meere J.J., and Roeyers H. ERP correlates of impaired error monitoring in children with ADHD. J. Neural. Transm. 112 (2005) 1417-1430
153. Wigal S.B., Swanson J.M., Feifel D., Sangal R.B., Elia J., Casat C.D., Zeldis J.B., and Conners C.K. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43 (2004) 1406-1414
154. Wigg K.G., Takhar A., Ickowicz A., Tannock R., Kennedy J.L., Pathare T., Malone M., Schachar R.J., and Barr C.L. Gene for the serotonin transporter and ADHD: no association with two functional polymorphisms. Am. J. Med. Genet. Part B 141B (2006) 566-570
155. Winstanley C.A., Theobald D.E.H., Dalley J.W., Cardinal R.N., and Robbins T.W. Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice. Cereb. Cortex 16 (2006) 106-114
156. Zametkin A.J., and Rapoport J.L. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?. J. Am. Acad. Child. Psychiatry 26 (1987) 676-686